Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Achilles Therapeutics

    NASDAQ: ACHL · Real-Time Price · USD
    1.48
    0.00 (0.00%)
    At close: Mar 20, 2025, 3:59 PM

    Achilles Therapeutics Statistics

    Share Statistics

    Achilles Therapeutics has 41.1M shares outstanding. The number of shares has increased by 0.03% in one year.

    Shares Outstanding

    n/a
    		 41.1M

    Shares Change (YoY)

    n/a
    		 0.03%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 60.1%

    Shares Floating

    n/a
    		 20.06M

    Failed to Deliver (FTD) Shares

    n/a
    		 5,471

    FTD / Avg. Volume

    n/a
    		 0.43%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -0.51 and the forward PE ratio is null. Achilles Therapeutics's PEG ratio is 0.12.

    PE Ratio

    n/a
    		 -0.51

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 0.25

    P/FCF Ratio

    n/a
    		 -0.72

    PEG Ratio

    n/a
    		 0.12
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Achilles Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.57, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 8.57

    Quick Ratio

    n/a
    		 8.57

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 -0.07

    Debt / FCF

    n/a
    		 -0.09

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-341,495.1

    Employee Count

    n/a
    		 204

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 4.73M

    Taxes

    Income Tax

    n/a
    		 491K

    Effective Tax Rate

    n/a
    		 -0.71%

    Stock Price Statistics

    The stock price has increased by 88.82% in the last 52 weeks. The beta is 1.25, so Achilles Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.25

    52-Week Price Change

    n/a
    		 88.82%

    50-Day Moving Average

    n/a
    		 1.32

    200-Day Moving Average

    n/a
    		 1.02

    Relative Strength Index (RSI)

    n/a
    		 76.37

    Average Volume (20 Days)

    n/a
    		 1,281,745

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -4.73M

    Operating Income

    n/a
    		 -75.25M

    Net Income

    n/a
    		 -69.67M

    EBITDA

    n/a
    		 -70.44M

    EBIT

    n/a
    		 -75.16M

    Earnings Per Share (EPS)

    n/a
    		 -1.74
    Full Income Statement

    Balance Sheet

    The company has 131.54M in cash and 4.62M in debt, giving a net cash position of 126.92M.

    Cash & Cash Equivalents

    n/a
    		 131.54M

    Total Debt

    n/a
    		 4.62M

    Net Cash

    n/a
    		 126.92M

    Retained Earnings

    n/a
    		 -259.95M

    Total Assets

    n/a
    		 122.68M

    Working Capital

    n/a
    		 93.16M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -48.45M and capital expenditures -1.1M, giving a free cash flow of -49.55M.

    Operating Cash Flow

    n/a
    		 -48.45M

    Capital Expenditures

    n/a
    		 -1.1M

    Free Cash Flow

    n/a
    		 -49.55M

    FCF Per Share

    n/a
    		 -1.24
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    ACHL does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ACHL is $4, which is 170.3% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $4

    Price Target Difference

    n/a
    		 170.3%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -2.67

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist